Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes
Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes
复制标题
DOI：
10.1007/s10384-009-0692-5
复制
发表时间：
2009-09-01
影响因子：
2.4
通讯作者：
Ogura, Yuichiro
中科院分区：
文献类型：
--
作者：
Hirano, Yoshio;Ito, Takeshi;Ogura, Yuichiro
旨在评估曲安奈德（TA）给药后眼压（IOP）升高的发生率和危险因素。在这个回顾性观察病例系列中，患有弥漫性糖尿病黄斑水肿（66只眼）、视网膜分支静脉阻塞（39只眼）、视网膜中央静脉阻塞（25只眼）、渗出性年龄相关性黄斑变性（49只眼）、近视的患者（202名患者中的224只眼）脉络膜新生血管（10只眼）、葡萄膜炎（30只眼）或其他病症（5只眼）接受玻璃体内或后Tenon囊下注射，或两者同时注射TA。 106只眼（STTA组）进行Tenon囊下注射。 118只眼（IVTA组）进行玻璃体内注射，其中85只眼同时进行玻璃体内和Tenon囊下注射。 TA 给药后的平均随访时间为 15.9 +/- 10.4（范围，3-39）个月。比较Tenon囊下注射和玻璃体内注射TA的IOP升高频率以及TA给药与初始IOP升高之间的时间，并确定导致IOP升高的可能危险因素。STTA组和IVTA组IOP>21 mmHg的频率无显着差异（P = 0.0588）。然而，两组之间 IOP > 30 mmHg 的频率存在显着差异 (P = 0.0004)。在 IVTA 组中，需要抗青光眼药物的患者多于 STTA 组 (P = 0.0052)。 IVTA组TA给药后1周内眼压升高发生率显着高于STTA组（P=0.0154）。眼压升高的危险因素包括较高的基线眼压（P < 0.0001）、年轻患者（P = 0.0095）以及同时进行Tenon囊下注射和玻璃体内注射（P = 0.0228）。TA注射后需要仔细随访眼压。
To evaluate the incidence and risk factors of intraocular pressure (IOP) elevation following triamcinolone acetonide (TA) administration.In this retrospective observational case series, patients (224 eyes of 202 patients) with diffuse diabetic macular edema (66 eyes), branch retinal vein occlusion (39 eyes), central retinal vein occlusion (25 eyes), exudative age-related macular degeneration (49 eyes), myopic choroidal neovascularization (10 eyes), uveitis (30 eyes), or other conditions (5 eyes) were administered an intravitreal or posterior sub-Tenon capsule injection, or both, of TA. Sub-Tenon capsule injection was performed on 106 eyes (STTA group). Intravitreal injection was performed on 118 eyes (IVTA group), of which 85 eyes underwent simultaneous intravitreal and sub-Tenon capsule injections. Mean follow-up after TA administration was 15.9 +/- 10.4 (range, 3-39) months. The sub-Tenon capsule injection and intravitreal injection of TA were compared with respect to the frequency of IOP elevation and the time between TA administration and the initial IOP elevation, and the possible risk factors responsible for IOP elevation were identified.There was no significant difference in frequency of IOP > 21 mmHg between the STTA group and the IVTA group (P = 0.0588). There was, however, a significant difference in the frequency of IOP > 30 mmHg between the two groups (P = 0.0004). In the IVTA group, more patients needed antiglaucoma medication than in the STTA group (P = 0.0052). The incidence rate of IOP elevation within 1 week after TA administration in the IVTA group was significantly higher than in the STTA group (P = 0.0154). Risk factors for IOP elevation included higher baseline IOP (P < 0.0001), younger patients (P = 0.0095), and simultaneous administration of sub-Tenon capsule and intravitreal injections (P = 0.0228).Careful follow-up of IOP is required after TA injections.